DXCM · PEAD ↑ 80

Dexcom reported Q2 2026 EPS of $0.70 on 2026-07-30, beating the $0.61 consensus by $0.09 (+14.8%).

Print-day reaction was a modest -0.8% versus the prior close, as the after-market report left the regular-session close essentially flat on earnings day. The overnight gap into T+1 open was a decisive +7.2%, signalling that the market absorbed the beat and re-priced sharply higher before the next regular session opened. The Day 1–3 drift added a further +4.2%, confirming the gap rather than fading it, with the stock pushing steadily from $79.88 to $86.94. Cumulative abnormal return of +9.96% versus SPY.US firmly places this in PEAD long territory; per the documented pattern, the read holds through 2026-10-27.